Drug Profile

PF 07059013

Alternative Names: PF-07059013

Latest Information Update: 18 Feb 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pfizer
Class Antianaemics
Mechanism of Action Haemoglobin modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Sickle cell anaemia
New Molecular Entity Yes

Highest Development Phases

Discontinued Sickle cell anaemia

Most Recent Events

08 Feb 2022 Discontinued - Phase-I for Sickle cell anaemia (In volunteers, In adults) in Belgium (PO)
08 Feb 2022 Discontinued - Preclinical for Sickle cell anaemia in USA (PO)
13 May 2021 PF 07059013 receives Orphan Drug status for Sickle cell anaemia in USA prior to May 2021 (Pfizer pipeline, May 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com